ASH 2022 | MonumenTAL-1: talquetamab in R/R multiple myeloma

G protein-coupled receptor family C group 5 member D (GPRC5D) has limited expression in normal human tissue but is highly expressed on malignant plasma cells, making it a promising immunotherapy target for patients with multiple myeloma. Talquetamab is a T-cell bispecific antibody targeting both GPRC5D and CD3 receptors. Ajai Chari, MD, Mount Sinai School of Medicine, New York, NY, outlines findings of MonumenTAL-1 (NCT03399799/NCT04634552), a Phase I/II trial of talquetamab in patients with relapsed/ refractory (R/R) multiple myeloma. 143 patients were treated at 0.4 mg/kg weekly. The median age of patients was 67 years, and all had received a median of 5 prior lines of treatment. Results showed that responses were durable and deepened over time, with the overall response rate (ORR) being 73%. Median time to complete response (CR) was 2.1 months, while the median progression-free survival (PFS) was 7.5 months. The most common adverse events (AEs) were CRS, dysgeusia and anemia; skin-related AEs and nail disorders were also observed in a number of patients. Cytopenias, including neutropenia and thrombocytopenia were also recorded but were generally limited to the first few cycles. Overall, talquetamab demonstrated robust efficacy and manageable safety in patients with heavily pretreated R/R multiple myeloma. This press briefing took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.